{ "model": { "rank": 8791, "code": "thing-q816798", "model_id": "vr.tr.amyloidosis", "name": "amyloidosis", "purpose": "Let an agent give general, sourced information about amyloidosis, route urgent symptoms to emergency care, point to specialist centres and support groups, and avoid personal medical advice.", "family": "Thing Registry", "category": "Activities and processes", "status": "research-draft", "kind": "thing", "plane": "ACT", "domain": "ACT.PRC", "industry": "", "version": "", "url": "/models/thing/q816798/", "tier": 2, "score": 49, "payload": { "layer": "wikidata", "aliases": [ "amyloid tumor", "AL amyloidosis", "Primary systemic amyloidosis", "X-linked reticulate pigmentary disorder", "cutaneous lichen amyloidosis", "serum amyloid A amyloidosis", "Nasal amyloidosis", "cerebral amyloid angiopathy", "wild-type transthyretin amyloid", "Lect2 amyloidosis", "hereditary gelsolin amyloidosis", "amyloid neuropathy", "amyloidosis, cutaneous bullous", "AApoAIV amyloidosis", "ABeta2M amyloidosis", "AH amyloidosis", "amyloidosis bronchopulmonary", "amyloidosis nodular localized cutaneous", "Heredofamilial amyloidosis", "Organ-limited amyloidosis", "primary cutaneous amyloidosis", "Secondary cutaneous amyloidosis", "amyloid nephropathy", "familial cerebral amyloid angiopathy", "hereditary cystatin C amyloid angiopathy", "Hereditary cerebral hemorrhage with amyloidosis, Dutch type", "APP-related cerebral amyloid angiopathy", "ABri amyloidosis", "ADan amyloidosis", "Familial British dementia", "amyloid-beta related angiitis", "acquired amyloid peripheral neuropathy", "variant ABeta2M amyloidosis", "hereditary ATTR amyloidosis", "nodular cutaneous amyloidosis", "amyloidosis cutis dyschromia", "lichen amyloidosis" ], "aliasCount": 37, "merged": 37, "knownIn": 49, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": "vr.tr.amyloidosis", "source": { "dataset": "wikidata", "item": "Q816798", "url": "https://www.wikidata.org/wiki/Q816798", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-11T13:47:58Z", "providers": [ "Claude" ], "breadth": "written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify", "pass": 2, "wave": 1, "engine": "claude" }, "metaModel": { "id": "THING-Q816798", "registryId": "vr.tr.amyloidosis", "name": "amyloidosis", "version": "0.2.0-wave.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "ACT.PRC" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q816798/", "model": { "registry_id": "vr.tr.amyloidosis", "name": "amyloidosis", "purpose": "Let an agent give general, sourced information about amyloidosis, route urgent symptoms to emergency care, point to specialist centres and support groups, and avoid personal medical advice.", "definition": "A group of diseases in which abnormally folded proteins called amyloid build up in organs and tissues, such as AL amyloidosis from light chains, ATTR amyloidosis from transthyretin, hereditary or wild-type, and AA amyloidosis linked to chronic inflammation; effects depend on the organs involved, such as the heart, kidneys and nerves.", "what_it_is_for": "A group of rare diseases relevant to diagnosis, specialist care and support.", "affordances": [ "find general information about amyloidosis types", "recognise urgent symptoms", "find specialist centres", "find patient support organisations" ], "distinguishing_features": [ "Misfolded protein deposits", "Many types", "Can affect several organs", "Treated at specialist centres" ], "appearance": "Not visible directly; diagnosed by biopsy, imaging and laboratory tests.", "visual_identification": [ "Amyloid deposits in tissue samples", "Types named by the precursor protein", "Alzheimer amyloid plaques are a distinct topic" ], "physical_properties": [], "families_and_kinds": [ "AL amyloidosis", "ATTR amyloidosis (hereditary and wild-type)", "AA amyloidosis", "localised amyloidosis", "cutaneous amyloidosis" ], "related_models": [ { "relation": "is a kind of", "target": "systemic disease", "why": "category" }, { "relation": "is caused by", "target": "protein misfolding", "why": "mechanism" }, { "relation": "can affect", "target": "heart and kidneys", "why": "organs" }, { "relation": "is treated at", "target": "specialist amyloidosis centre", "why": "care" } ], "identifiers": [], "standards_and_regulation": [ "Clinical guidelines on amyloidosis", "Medicines regulation for new therapies", "Genetic counselling standards for hereditary forms" ], "failure_modes_and_hazards": [ "Delayed diagnosis", "Agents giving treatment advice", "Confusing types with different treatments" ], "in_scope": [], "out_of_scope": [], "characteristics": [] }, "sources": [], "structure": { "bundles": [ { "id": "urgent", "name": "Urgent", "description": "Urgent symptoms.", "rationale": "Safety comes first.", "layers": [ { "id": "heart", "name": "Heart", "description": "Cardiac symptoms.", "findings": [ { "id": "heart-finding", "name": "Heart", "description": "Cardiac symptoms.", "questions": [ { "text": "Is there chest pain, severe breathlessness or fainting?", "kind": "boundary" }, { "text": "Should emergency services be called now?", "kind": "action" } ] } ] }, { "id": "review", "name": "Review", "description": "Seeing a doctor.", "findings": [ { "id": "review-finding", "name": "Review", "description": "Medical review.", "questions": [ { "text": "Are there persistent symptoms such as swelling, numbness or frothy urine that need review?", "kind": "boundary" }, { "text": "Should the person see their doctor promptly?", "kind": "action" } ] } ] } ] }, { "id": "information", "name": "Information", "description": "General facts.", "rationale": "Sourced information only.", "layers": [ { "id": "types", "name": "Types", "description": "Kinds.", "findings": [ { "id": "types-finding", "name": "Types", "description": "Types.", "questions": [ { "text": "What do specialist centres say about this type of amyloidosis?", "kind": "provenance" }, { "text": "How is it diagnosed in general terms?", "kind": "definition" } ] } ] }, { "id": "personal", "name": "Personal", "description": "Personal questions.", "findings": [ { "id": "personal-finding", "name": "Personal", "description": "Personal advice limits.", "questions": [ { "text": "Is the user asking about their own diagnosis, treatment or prognosis?", "kind": "boundary" }, { "text": "How should the agent refer them to their specialist team?", "kind": "action" } ] } ] } ] }, { "id": "care", "name": "Care", "description": "Services.", "rationale": "Specialist care matters.", "layers": [ { "id": "centres", "name": "Centres", "description": "Specialist centres.", "findings": [ { "id": "centres-finding", "name": "Centres", "description": "Specialist centres.", "questions": [ { "text": "Which specialist amyloidosis centres serve this region?", "kind": "provenance" }, { "text": "How are referrals made?", "kind": "provenance" } ] } ] }, { "id": "genetics", "name": "Genetics", "description": "Hereditary forms.", "findings": [ { "id": "genetics-finding", "name": "Genetics", "description": "Hereditary forms.", "questions": [ { "text": "Should relatives consider genetic counselling for hereditary ATTR amyloidosis?", "kind": "provenance" }, { "text": "How can they access it?", "kind": "action" } ] } ] } ] }, { "id": "support", "name": "Support", "description": "Patients and families.", "rationale": "Support helps.", "layers": [ { "id": "groups", "name": "Groups", "description": "Support organisations.", "findings": [ { "id": "groups-finding", "name": "Groups", "description": "Support organisations.", "questions": [ { "text": "Which patient organisations support people with amyloidosis?", "kind": "provenance" }, { "text": "Do they run helplines?", "kind": "provenance" } ] } ] }, { "id": "trials", "name": "Trials", "description": "Clinical trials.", "findings": [ { "id": "trials-finding", "name": "Trials", "description": "Clinical trials.", "questions": [ { "text": "Which official registries list amyloidosis trials?", "kind": "provenance" }, { "text": "Who can discuss eligibility?", "kind": "action" } ] } ] } ] } ] }, "openQuestions": [ "Should each type be a separate entry?", "How should specialist centres be linked?", "How should new therapies be tracked?" ], "statistics": { "bundles": 4, "layers": 8, "findings": 8, "questions": 16 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "disease or condition", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a amyloidosis, record what state it is in, and decide what may be done with it.", "whatItIs": "Let an agent give general, sourced information about amyloidosis, route urgent symptoms to emergency care, point to specialist centres and support groups, and avoid personal medical advice.", "characteristics": { "substance": "activity", "origin": "conceptual", "agency": "inert" }, "whatYouCanDoWithIt": [ "observed and measured" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: amyloid tumor, AL amyloidosis, Primary systemic amyloidosis, X-linked reticulate pigmentary disorder, cutaneous lichen amyloidosis, serum amyloid A amyloidosis, Nasal amyloidosis, cerebral amyloid angiopathy, wild-type transthyretin amyloid, Lect2 amyloidosis, hereditary gelsolin amyloidosis, amyloid neuropathy.", "37 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 49 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a amyloidosis, and on what evidence are they told apart?" ], "whatItIsMadeOf": "something that happens over time", "physicalCharacter": [ "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state" ], "howItIsRecognised": [ "Recognised by criteria applied to signs and findings, not by appearance. Two conditions can look identical and be distinguished only by test." ], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "amyloid tumor", "AL amyloidosis", "Primary systemic amyloidosis", "X-linked reticulate pigmentary disorder", "cutaneous lichen amyloidosis", "serum amyloid A amyloidosis", "Nasal amyloidosis", "cerebral amyloid angiopathy", "wild-type transthyretin amyloid", "Lect2 amyloidosis", "hereditary gelsolin amyloidosis", "amyloid neuropathy" ] } ], "standing": "Described in 49 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 37 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one amyloidosis from another, and a amyloidosis from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a amyloidosis sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a amyloidosis from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a amyloidosis passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a amyloidosis between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a amyloidosis, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a amyloidosis is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "process-and-outcome", "name": "Process, inputs and outcome", "description": "How a amyloidosis proceeds, what it needs and what it leaves behind.", "rationale": "An activity is known by its steps and its results, and both have to be recordable while it is still running.", "layers": [ { "id": "steps-and-sequence", "name": "Steps and sequence", "description": "The steps of a amyloidosis, their order and what may run in parallel.", "findings": [ { "id": "steps-and-preconditions", "name": "Steps, preconditions and completion", "description": "What has to be true before each step of a amyloidosis and what marks it done.", "questions": [ { "id": "steps-and-preconditions-q01", "text": "What identifies and describes a step of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "steps-and-preconditions-q02", "text": "Who or what asserted this about a step of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "steps-and-preconditions-q03", "text": "What may an agent decide or do once a step of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "inputs-and-results", "name": "Inputs, resources and results", "description": "What a amyloidosis consumes and what it produces.", "findings": [ { "id": "inputs-and-outputs", "name": "Inputs, outputs and side effects", "description": "The resources a amyloidosis takes and the results it leaves, wanted or not.", "questions": [ { "id": "inputs-and-outputs-q01", "text": "What identifies and describes the inputs and results of a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "inputs-and-outputs-q02", "text": "Who or what asserted this about the inputs and results of a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "inputs-and-outputs-q03", "text": "What may an agent decide or do once the inputs and results of a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "diagnosis-and-criteria", "name": "Diagnosis, criteria and coding", "description": "What makes a case of amyloidosis a case, and under which revision.", "rationale": "Criteria change between revisions, so a diagnosis without its coding revision cannot be compared with a later one.", "layers": [ { "id": "criteria", "name": "Diagnostic criteria", "description": "The criteria in force and who issues them.", "findings": [ { "id": "criteria-record", "name": "Criteria, issuer and revision", "description": "What must be true for a diagnosis, according to whom.", "questions": [ { "id": "criteria-record-q01", "text": "What criteria define amyloidosis, issued by which body, in which revision?", "kind": "definition" }, { "id": "criteria-record-q02", "text": "What changed between revisions that would reclassify existing cases?", "kind": "boundary" } ] } ] }, { "id": "coding", "name": "Coding and terminology", "description": "The codes used to record it and their mapping.", "findings": [ { "id": "coding-record", "name": "Codes and mappings", "description": "Which classification codes apply and how they map.", "questions": [ { "id": "coding-record-q01", "text": "Which classification and terminology codes cover amyloidosis, and how do they map to each other?", "kind": "definition" }, { "id": "coding-record-q02", "text": "What is lost when a case is mapped from one scheme to another?", "kind": "boundary" } ] } ] } ] }, { "id": "course-and-population", "name": "Course, population and care", "description": "How amyloidosis develops, whom it affects, and what is done about it.", "rationale": "The condition, the diagnosis and the episode of care are three different things, and an agent must not merge them.", "layers": [ { "id": "course", "name": "Course and stages", "description": "Onset, progression, remission and outcome.", "findings": [ { "id": "course-record", "name": "Stages and transitions", "description": "The stages recorded and what moves a case between them.", "questions": [ { "id": "course-record-q01", "text": "What course does amyloidosis typically take, and what marks each stage?", "kind": "definition" }, { "id": "course-record-q02", "text": "What separates the condition itself from an episode of care for it?", "kind": "boundary" } ] } ] }, { "id": "population", "name": "Affected populations", "description": "Who is affected, how often, and on what evidence.", "findings": [ { "id": "epidemiology", "name": "Prevalence and its basis", "description": "Rates with their population, period and source.", "questions": [ { "id": "epidemiology-q01", "text": "What prevalence or incidence is reported for amyloidosis, in which population and period?", "kind": "measurement" }, { "id": "epidemiology-q02", "text": "What may an agent not conclude about an individual from a population rate?", "kind": "action" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a amyloidosis came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a amyloidosis and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a amyloidosis is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a amyloidosis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a amyloidosis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a amyloidosis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 6, "layers": 12, "findings": 14, "questions": 38 } } } }